ClinicalTrials.gg
CompletedNCT02504216VOYAGER PADUpdated Dec 8, 2020Results posted

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

A Phase 3 interventional study of Rivaroxaban (Xarelto, BAY59-7939) and Rivaroxaban-Placebo in Peripheral Artery Disease, sponsored by Bayer. Completed at 533 sites in 34 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by Bayer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
6,564
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing rivaroxaban in Peripheral Arterial Disease — 3 open to participants now, 3 under way, none of them phase 3. Rivaroxaban · Peripheral Arterial Disease.

Enrollment
2nd of 13
6,564 · median 100
Started
2015
the only one that year
Phase 3
2 of 13
none open now
Registered
2nd of 13
by date
Lead sponsor
2 of 13
Bayer

Among the 13 studies testing rivaroxaban in Peripheral Arterial Disease, this one is the 2nd largest by enrollment, is the only one that started in 2015, is one of 2 in phase 3, and was the 2nd registered.

Peripheral Arterial Disease

1,377 studies on the registry are indexed under Peripheral Arterial Disease; 275 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

3 of the 13 studies testing rivaroxaban in Peripheral Arterial Disease are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 192 Peripheral Arterial Disease studies recruiting now, 138 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing rivaroxaban in Peripheral Arterial Disease, or all of them as a file.
02

Study summary

The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.

03

Conditions studied

  • Peripheral Artery Disease

Keywords

  • Rivaroxaban
  • Xarelto
  • Aspirin
  • Acetylic salicylic acid
  • Anticoagulant
  • Peripheral artery disease
  • Peripheral arterial disease
  • Revascularization
  • Acute limb ischemia
  • Amputation
  • Cardiovascular events
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥50
  • Documented moderate to severe symptomatic lower extremity atherosclerotic peripheral artery disease
  • Technically successful peripheral revascularization distal to the external iliac artery for symptomatic PAD (Peripheral artery disease) within the last 10 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Patients undergoing revascularization for asymptomatic PAD or mild claudication without functional limitation of the index leg.
  • Patients undergoing revascularization of the index leg to treat an asymptomatic or minimally symptomatic restenosis of a bypass graft or target lesion restenosis.
  • Prior revascularization on the index leg within 10 days of the qualifying revascularization.
  • Planned dual antiplatelet therapy (DAPT) use for the qualifying revascularization procedure of clopidogrel in addition to Acetylic salicylic acid (ASA) for >6 months after the qualifying revascularization procedure; it is strongly recommended that any course of clopidogrel is kept to the minimum necessary in accordance with local standard of care and international practice guidelines (typically 30 days, or up to 60 days for some drug-coated products or devices) and is only allowed for up to 6 months for complex procedures or devices in the investigator's opinion that require longer use.
  • Planned use of any additional antiplatelet agent other than clopidogrel and ASA after the qualifying revascularization procedure.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
6,564 participants (actual)

Study arms

  • Experimental
    Rivaroxaban

    Rivaroxaban 2.5 mg orally twice daily (5 mg cumulative daily dose)

    Drug: Rivaroxaban (Xarelto, BAY59-7939)

  • Placebo comparator
    Placebo

    Rivaroxaban-placebo orally twice daily

    Drug: Rivaroxaban-Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.

  2. Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).

Secondary outcomes

  1. Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.

  2. Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.

  3. Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days

  4. Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days

  5. Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days

  6. Number of Mortality (All-cause)

    Time frame: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days

  7. Number of Participants With Venous Thromboembolic (VTE) Events

    Venous thromboembolic events were reported by investigator only.

    Time frame: For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days

  8. Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

    Time frame: For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).

  9. Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events

    Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered

    Time frame: For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)

07

Results

Posted Dec 8, 2020

Participant flow

Study was conducted at 548 centers which screened participants (534 sites randomized participants) worldwide between 18 Aug 2015 (first patient's first visit) and 27 Nov 2019 (last patient's last visit).

Participant flow — Overall Study
MilestoneRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Started32863278
Received treatment32563248
Completed32753263
Not completed1115
Withdrew: Lost to follow-up33
Withdrew: Withdrawal by subject812

Outcome measures

PrimaryPrimary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean time in follow-up survival time until ECOD that date was 1109.76 days.
Reported as:
Count of participants · Participants
Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Primary Efficacy Outcome: Number of Participants With Composite of Myocardial Infarction (MI), Ischemic Stroke, Cardiovascular Death, Acute Limb Ischemia (ALI) and Major Amputation Due to a Vascular Etiology508584
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0043 · Hazard ratio (hr): 0.85 · 95% CI 0.76 to 0.96P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.
PrimaryPrimary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the primary safety outcome after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
Reported as:
Count of participants · Participants
Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Primary Safety Outcome: Number of Participants With TIMI (Thrombolysis in Myocardial Infarction) Major Bleeding6244
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0695 · Hazard ratio (hr): 1.43 · 95% CI 0.97 to 2.10P-value (2-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.
SecondaryNumber of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.79 days.
Reported as:
Count of participants · Participants
Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Participants With Composite of MI, Ischemic Stroke, Coronary Heart Disease (CHD) Death, ALI, and Major Amputation of a Vascular Etiology433528
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0004 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 0.80 · 95% CI 0.71 to 0.91
SecondaryNumber of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1062.48 days.
Reported as:
Count of participants · Participants
Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Participants With an Unplanned Index Limb Revascularization for Recurrent Limb Ischemia (Subsequent Index Leg Revascularization That Was Not Planned or Considered as Part of the Initial Treatment Plan at the Time of Randomization)584655
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0140 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 0.88 · 95% CI 0.79 to 0.99
SecondaryNumber of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1154.04 days
Reported as:
Count of participants · Participants
Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Participants With Hospitalization for a Coronary or Peripheral Cause (Either Lower Limb) of a Thrombotic Nature262356
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = <0.0001 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 0.72 · 95% CI 0.62 to 0.85
SecondaryNumber of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1085.13 days
Reported as:
Count of participants · Participants
Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Participants With Composite of MI, Ischemic Stroke, All-cause Mortality (ACM), ALI, and Major Amputation of a Vascular Etiology614679
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0145 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 0.89 · 95% CI 0.79 to 0.99
SecondaryNumber of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the composite efficacy outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1108.29 days
Reported as:
Count of participants · Participants
Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Participants With Composite of MI, All-cause Stroke, Cardiovascular (CV) Death, Acute Limb Ischemia (ALI), and Major Amputation of a Vascular Etiology514588
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0051 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 0.86 · 95% CI 0.76 to 0.96
SecondaryNumber of Mortality (All-cause)
Time frame:
For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1188.48 days
Reported as:
Count of participants · Participants
Number of Mortality (All-cause)
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Mortality (All-cause)321297
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.8322 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 1.08 · 95% CI 0.92 to 1.27
SecondaryNumber of Participants With Venous Thromboembolic (VTE) Events

Venous thromboembolic events were reported by investigator only.

Time frame:
For each participant, the first occurrence of the outcome after randomization up until the efficacy cut-off date (08-Sep-2019) was considered. The mean survival time until ECOD was 1187.65 days
Reported as:
Count of participants · Participants
Number of Participants With Venous Thromboembolic (VTE) Events
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Number of Participants With Venous Thromboembolic (VTE) Events2541
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0235 (P-value (1-sided) is based on the log rank test stratified by type of procedure and clopidogrel use per IxRS assignment with treatment as a factor.) · Hazard ratio (hr): 0.61 · 95% CI 0.37 to 1.00
SecondarySecondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered.

Time frame:
For each participant, the first occurrence of the major bleeding events according to the ISTH classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo).
Reported as:
Count of participants · Participants
Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Secondary Safety Outcome: Number of Participants With ISTH (International Society on Thrombosis and Haemostasis) Major Bleeding140100
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0068 · Hazard ratio (hr): 1.42 · 95% CI 1.10 to 1.84
SecondarySecondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events

Only the first occurrence of the outcome event under analysis within the data scope from a participant is considered

Time frame:
For each participant, the first occurrence of the type 3b and above bleeding events according to the BARC classification after randomization up until 2 days after permanent stop of study drug (rivaroxaban or rivaroxaban placebo)
Reported as:
Count of participants · Participants
Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events
ParticipantsRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Secondary Safety Outcome: Number of Participants With BARC (Bleeding Academic Research Consortium) Type 3b and Above Bleeding Events9373
Statistical analysis
  • Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od vs Rivaroxaban Placebo Bid + Aspirin 100 mg od · Log Rank · p = =0.0979 · Hazard ratio (hr): 1.29 · 95% CI 0.95 to 1.76

Adverse events

Collected over From randomization until 2 days following permanent discontinuation of the study drug. Non-serious events are listed at a 0.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rivaroxaban 2.5 mg Bid + Aspirin 100 mg od327/3,256 (10%)948/3,256 (29.1%)725/3,256 (22.3%)
Rivaroxaban Placebo Bid + Aspirin 100 mg od304/3,248 (9.4%)927/3,248 (28.5%)729/3,248 (22.4%)
Most frequent serious events
Showing 10 of 776
Most frequent serious events
EventRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Peripheral arterial occlusive diseaseVascular disorders125/3256130/3248
Intermittent claudicationVascular disorders43/325652/3248
PneumoniaInfections and infestations40/325645/3248
Peripheral ischaemiaVascular disorders34/325629/3248
Postoperative wound infectionInfections and infestations27/325625/3248
Peripheral artery stenosisVascular disorders25/325614/3248
Carotid artery stenosisNervous system disorders22/325624/3248
Coronary artery diseaseCardiac disorders15/325621/3248
Atrial fibrillationCardiac disorders19/325620/3248
GangreneInfections and infestations16/325620/3248
Most frequent other events
Showing 10 of 141
Most frequent other events
EventRivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg od
Pain in extremityMusculoskeletal and connective tissue disorders47/325652/3248
HypertensionVascular disorders49/325650/3248
Atrial fibrillationCardiac disorders31/325648/3248
Intermittent claudicationVascular disorders39/325643/3248
Peripheral arterial occlusive diseaseVascular disorders34/325631/3248
ArthralgiaMusculoskeletal and connective tissue disorders18/325632/3248
NasopharyngitisInfections and infestations21/325630/3248
Back painMusculoskeletal and connective tissue disorders23/325630/3248
AnaemiaBlood and lymphatic system disorders29/325623/3248
DizzinessNervous system disorders23/325626/3248

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg odTotal
Median67.0 (49 to 93)67.0 (50 to 95)67 (49 to 95)
Sex: Female, Male
Sex: Female, Male(Participants)Rivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg odTotal
Female8478571704
Male243924214860
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rivaroxaban 2.5 mg Bid + Aspirin 100 mg odRivaroxaban Placebo Bid + Aspirin 100 mg odTotal
American Indian or Alaska Native145
Asian484482966
Native Hawaiian or Other Pacific Islander011
Black or African American8471155
White264726565303
More than one race123
Unknown or Not Reported6962131
08

Study locations

533 sites
  • Alexander City, Alabama 35010, United States
  • Birmingham, Alabama 35294-0012, United States
  • Fort Payne, Alabama 35967, United States
  • Huntsville, Alabama 35801-4317, United States
  • Avondale, Arizona 85388, United States
  • Glendale, Arizona 85340, United States
  • Phoenix, Arizona 85006, United States
  • Mission Viejo, California 92691, United States
  • Northridge, California 91325, United States
  • Palo Alto, California 94304, United States
  • Roseville, California 95661, United States
  • Stanford, California 94305, United States
  • Torrance, California 90502, United States
  • Aurora, Colorado 80045, United States
  • Denver, Colorado 80220, United States
  • Washington, District of Columbia 20007, United States
  • Washington, District of Columbia 20422, United States
  • Atlantis, Florida 33462, United States
  • Clearwater, Florida 33756, United States
  • Daytona Beach, Florida 32117, United States
  • Gainesville, Florida 32605, United States
  • Hudson, Florida 34667, United States
  • Jacksonville, Florida 32209, United States
  • Jacksonville, Florida 32216, United States
  • Miami, Florida 33173, United States
  • Ocala, Florida 34474, United States
  • Pensacola, Florida 32501, United States
  • Safety Harbor, Florida 34695, United States
  • Tallahassee, Florida 32308, United States
  • Wellington, Florida 33449, United States
  • Arlington Heights, Illinois 60005, United States
  • Elk Grove Village, Illinois 60007, United States
  • Springfield, Illinois 62701, United States
  • Springfield, Illinois 62702, United States
  • Urbana, Illinois 61801, United States
  • Fort Wayne, Indiana 46804, United States
  • Fort Wayne, Indiana 46845, United States
  • Merrillville, Indiana 46410, United States
  • Iowa City, Iowa 52242, United States
  • Lexington, Kentucky 40536, United States
  • Alexandria, Louisiana 71301, United States
  • Covington, Louisiana 70433, United States
  • Shreveport, Louisiana 71103, United States
  • Shreveport, Louisiana 71105, United States
  • Lewiston, Maine 04240, United States
  • Baltimore, Maryland 21201-1595, United States
  • Baltimore, Maryland 21218, United States
  • Clinton, Maryland 20735, United States
  • Bay City, Michigan 48708, United States
  • Dearborn, Michigan 48126, United States
  • Detroit, Michigan 48201, United States
  • Lansing, Michigan 48912, United States
  • Midland, Michigan 48670, United States
  • Muskegon, Michigan 49444, United States
  • Wyoming, Michigan 49519, United States
  • Coon Rapids, Minnesota 55433, United States
  • Saint Cloud, Minnesota 56303, United States
  • Jackson, Mississippi 39216, United States
  • Tupelo, Mississippi 38801, United States
  • Saint Louis, Missouri 63128, United States
  • Springfield, Missouri 65807, United States
  • Lincoln, Nebraska 68506, United States
  • Lincoln, Nebraska 68510, United States
  • Lebanon, New Hampshire 03756-0001, United States
  • Flemington, New Jersey 08822, United States
  • Linden, New Jersey 07036, United States
  • Teaneck, New Jersey 07666, United States
  • New York, New York 10011, United States
  • New York, New York 10029, United States
  • Saratoga Springs, New York 12866, United States
  • Chapel Hill, North Carolina 27517, United States
  • Charlotte, North Carolina 28204, United States
  • Durham, North Carolina 27710, United States
  • Winston-Salem, North Carolina 27103, United States
  • Minot, North Dakota 58701, United States
  • Cincinnati, Ohio 45219, United States
  • Cincinnati, Ohio 45267, United States
  • Dayton, Ohio 45414, United States
  • Springfield, Ohio 45505, United States
  • Toledo, Ohio 43614, United States
  • Oklahoma City, Oklahoma 73135, United States
  • Hillsboro, Oregon 97123, United States
  • Camp Hill, Pennsylvania 17011, United States
  • Erie, Pennsylvania 16507, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Philadelphia, Pennsylvania 19140, United States
  • York, Pennsylvania 17405, United States
  • Greenville, South Carolina 29657, United States
  • Rapid City, South Dakota 57702, United States
  • Knoxville, Tennessee 37934, United States
  • Amarillo, Texas 79106, United States
  • Austin, Texas 78705, United States
  • Dallas, Texas 75216-7167, United States
  • Dallas, Texas 75226, United States
  • Edinburg, Texas 78539, United States
  • Houston, Texas 77030, United States
  • Humble, Texas 77338, United States
  • Huntsville, Texas 77340, United States
  • Kingwood, Texas 77339, United States
  • San Antonio, Texas 78258, United States

Showing the first 100 of 533 sites across 34 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Hess CN, Baumgartner I, Anand SS, Nehler MR, Patel MR, Debus ES, Szarek M, Capell W, Muehlhofer E, Berkowitz SD, Haskell LP, Bauersachs RM, Bonaca MP, Hsia J. Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Heart Assoc. 2022 Jun 21;11(12):e024655. doi: 10.1161/JAHA.121.024655. Epub 2022 Jun 14. PubMed 35699170 ↗
  • Hogan SE, Nehler MR, Anand S, Patel MR, Debus S, Jackson MT, Buchanan C, King RW, Hess C, Muehlhofer E, Haskell LP, Bauersachs RM, Berkowitz SD, Hsia J, Bonaca MP. Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. Vasc Med. 2022 Aug;27(4):343-349. doi: 10.1177/1358863X221085606. Epub 2022 Apr 25. PubMed 35467452 ↗
  • Hess CN, Patel MR, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Fanelli F, Yeh RW, Secemsky EA, Beckman JA, Mauri L, Govsyeyev N, Capell WH, Brackin T, Berkowitz SD, Muehlhofer E, Haskell LP, Hiatt WR, Bonaca MP. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 Nov 2;78(18):1768-1778. doi: 10.1016/j.jacc.2021.08.052. PubMed 34711335 ↗
  • Debus ES, Nehler MR, Govsyeyev N, Bauersachs RM, Anand SS, Patel MR, Fanelli F, Capell WH, Brackin T, Hinterreiter F, Krievins D, Nault P, Piffaretti G, Svetlikov A, Jaeger N, Hess CN, Sillesen HH, Conte M, Mills J, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation. 2021 Oct 5;144(14):1104-1116. doi: 10.1161/CIRCULATIONAHA.121.054835. Epub 2021 Aug 12. PubMed 34380322 ↗
  • Bauersachs RM, Szarek M, Brodmann M, Gudz I, Debus ES, Nehler MR, Anand SS, Patel MR, Hess CN, Capell WH, Rogers K, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP; VOYAGER PAD Committees and Investigators. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol. 2021 Jul 27;78(4):317-326. doi: 10.1016/j.jacc.2021.05.003. Epub 2021 May 16. PubMed 34010631 ↗
  • Hiatt WR, Bonaca MP, Patel MR, Nehler MR, Debus ES, Anand SS, Capell WH, Brackin T, Jaeger N, Hess CN, Pap AF, Berkowitz SD, Muehlhofer E, Haskell L, Brasil D, Madaric J, Sillesen H, Szalay D, Bauersachs R. Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization: Impact of Concomitant Clopidogrel on Efficacy and Safety. Circulation. 2020 Dec 8;142(23):2219-2230. doi: 10.1161/CIRCULATIONAHA.120.050465. Epub 2020 Nov 3. PubMed 33138628 ↗
  • Bonaca MP, Bauersachs RM, Anand SS, Debus ES, Nehler MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Matyas L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020 May 21;382(21):1994-2004. doi: 10.1056/NEJMoa2000052. Epub 2020 Mar 28. PubMed 32222135 ↗
  • Capell WH, Bonaca MP, Nehler MR, Chen E, Kittelson JM, Anand SS, Berkowitz SD, Debus ES, Fanelli F, Haskell L, Patel MR, Bauersachs R, Hiatt WR. Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). Am Heart J. 2018 May;199:83-91. doi: 10.1016/j.ahj.2018.01.011. Epub 2018 Feb 3. PubMed 29754671 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Nov 2019, 51 months.

Results were first posted in Dec 2020, 1 year after primary completion.

Of 26 phase 3 interventional studies under Peripheral Arterial Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 58. This study's 51 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2015
First posted
Jul 21, 2015
StartActual
Aug 18, 2015
Primary completionActual
Nov 27, 2019
CompletionActual
Jan 9, 2020
Results first posted
Dec 8, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02504216
Lead sponsor
Bayer
Collaborators
Janssen Research & Development, LLC, Colorado Prevention Center
Responsible party
Sponsor
First posted
Jul 21, 2015
Start date
Aug 18, 2015
Primary completion
Nov 27, 2019
Completion
Jan 9, 2020
Results posted
Dec 8, 2020
Last update
Dec 8, 2020

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rivaroxaban

Start the discussion